Featured Cover

Bergh, Peter Van den; Doorn, Pieter A. van; Hadden, Robert D.M.; Avau, Bert; Vankrunkelsven, Patrik; Allen, Jeffrey A.; Attarian, Shahram; Blomkwist‐Markens, Patricia H.; Cornblath, David R.; Eftimov, Filip; Goedee, H. Stephan; Harbo, Thomas; Kuwabara, Satoshi; Lewis, Richard A.; Lunn, Michael P.; Nobile‐Orazio, Eduardo; Querol, Luís; Rajabally, Yusuf A.; Sommer, Claudia; Topaloğlu, Haluk

doi:10.1111/jns.12466

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Demographics, clinical features, electrodiagnostic and laboratory findings of all cohorts are summarized in Tables 1, 2. 6 GBS, Guillain-Barrésyndrome; CIDP, chronic inflammatory demyelinating polyneuropathy; PDN, paraproteinemia-related demyelinating polyneuropathy; MMN, multifocal motor neuropathy; HC, healthy controls; NIP, non-inflammatory polyneuropathies (the NIP group in the Multiplex replication cohort consisted of hereditary demyelinating and axonal neuropathies, and in the ELISA cohort of chronic idiopathic axonal polyneuropathies and hereditary demyelinating and axonal neuropathies); MS, multiple sclerosis; ALS, amyotrophic lateral sclerosis; Q.alb, albumin quotient (CSF/plasma quotient of albumin); OCB, oligoclonal bands; NA, not applicable; abs, antibodies. 1 IgG or IgA, 2 IgM, of which all with MAG-abs, 3 IgG anti-GQ1b, 4 IgM anti-GD1b, IgM anti-GM1, IgM anti-GM2, IgM anti-GQ1b, 5 IgM anti-GM1, 6 melanoma 22 years prior to GBS, prostate cancer 5 years prior to CIDP, and 3 years prior to PDN, breast cancer 6 years prior to ALS, 7 Graves' disease 6 years prior to CIDP, 6 years prior to ALS, 5 years prior to sample collection in patient with NIP; *mean ± standard deviation (SD).…”

Section: Study Cohortmentioning

confidence: 99%

“…The search for diagnostic and prognostic biomarkers in inflammatory neuropathies is a growing research field (1-3), prompted by the fact that the diagnosis of Guillain-Barreś yndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are merely based on clinical features and nerve conduction studies, and lack disease-specific blood and cerebrospinal fluid (CSF) findings (4)(5)(6).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay

Kmezic,

Gustafsson,

Fink

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundBiomarkers for diagnosis of inflammatory neuropathies, assessment of prognosis, and treatment response are lacking.MethodsCSF and EDTA plasma from patients with Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), healthy controls (HC) and disease controls were analyzed with Olink multiplex proximity extension assay (PEA) from two independent cohorts. Levels of interleukin-8 (IL8) were further analyzed with ELISA in patients with GBS, CIDP, paraproteinemia-related demyelinating polyneuropathy (PDN), multifocal motor neuropathy (MMN), HC and disease controls. ROC analysis was performed. Outcome was measured with the GBS-disability score (GBS-ds) or Inflammatory Neuropathy Cause and Treatment (INCAT) score.ResultsIn CSF, multiplex PEA analysis revealed up-regulation of IL8 in GBS compared to CIDP and HC respectively, and CIDP compared to HC. In addition, levels of IL2RA were upregulated in GBS compared to both HC and CIDP, SELE in GBS compared to HC, and ITGAM, IL6, and NRP1 in GBS compared to CIDP. In plasma, levels of MMP3, THBD and ITGAM were upregulated in CIDP compared to HC. Validation of multiplex IL8 results using ELISA, revealed increased levels of IL8 in CSF in patients with GBS and CIDP versus HC and non-inflammatory polyneuropathies (NIP) respectively, as well as in PDN versus NIP and HC. Levels of IL8 in CSF correlated with impairment in the acute phase of GBS as well as outcome at 6-months follow up.ConclusionIL8 in CSF is validated as a diagnostic biomarker in GBS and CIDP, and a prognostic biomarker in GBS. Multiplex PEA hereby identifies several potential biomarkers in GBS and CIDP.

show abstract

Section: Study Cohortmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay

Kmezic,

Gustafsson,

Fink

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Typical CIDP is more prevalent in men and can occur at any age, with the highest prevalence reported in the middle ages (30-60 years of age) (7,8). The history of the disease is consistently progressive for more than 8 weeks but can be relapsing-remitting (9,10).…”

Section: Introductionmentioning

confidence: 99%

Central nervous system involvement in chronic inflammatory demyelinating polyradiculoneuropathy—MRS and DTI study

Dziadkowiak,

Koszewicz,

Podgórski

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

ObjectiveThe current research aimed to analyze the alterations within the motor cortex and pyramidal pathways and their association with the degree of damage within the peripheral nerve fibers in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). To achieve that goal, we investigated the microstructural changes within the pyramidal white matter tracts using diffusion tensor imaging (DTI) parameters, evaluated metabolic alterations in both precentral gyri using magnetic resonance spectroscopy (MRS) ratios, and correlated them with the neurographic findings in patients with CIDP.MethodsThe spectroscopic ratios of NAA/Cr, Cho/Cr, and mI/Cr from both precentral gyri and the values of fractional anisotropy (FA), axial diffusivity (AD), and mean diffusivity (MD) from both of the corticospinal tracts were correlated with the results of neurological and neurographic findings. The comparison of DTI parameters between the patients and controls was performed using Student’s t-test or the Mann–Whitney U test. Due to the lack of normal distribution of most variables, Spearman’s Rho rank coefficient was used to test all correlations. All analyses were performed at a significant level of alpha = 0.05 using STATISTICA 13.3.ResultsCompared to the control group (CG), the patient group showed significantly lower ratios of NAA/Cr (1.66 ± 0.11 vs. 1.61 ± 0.15; p = 0.022), higher ratios of ml/Cr in the right precentral gyrus (0.57 ± 0.15 vs. 0.61 ± 0.08; p = 0.005), and higher levels of Cho/Cr within the left precentral gyrus (0.83 ± 0.09 vs. 0.88 ± 0.14, p = 0.012). The DTI parameters of MD from the right CST and AD from the right and left CSTs showed a strong positive correlation (0.52–0.53) with the sural sensory nerve action potential (SNAP) latency of the right sural nerve. There were no other significant correlations between other DTI and MRS parameters and neurographic results.SignificanceIn our study, significant metabolic alterations were found in the precentral gyri in patients with CIDP without clinical symptoms of central nervous system involvement. The revealed changes reflected neuronal loss or dysfunction, myelin degradation, and increased gliosis. Our results suggest coexisting CNS damage in these patients and may provide a new insight into the still unknown pathomechanism of CIDP.

show abstract

Featured Cover

Cited by 2 publications

References 0 publications

Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay

Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay

Central nervous system involvement in chronic inflammatory demyelinating polyradiculoneuropathy—MRS and DTI study

Contact Info

Product

Resources

About